Table 1 Comparison of clinical features and qualitative analysis of serum tumor markers between EGFR wild-type and mutant-type male patients with NSCLC
Characteristics | Total | EGFR | P value | |
|---|---|---|---|---|
Wild-type | Mutant-type | |||
Age, years | Â | Â | Â | 0.405 |
 Median | 67 | 67 | 68 |  |
 Range | 35–85 | 35–81 | 44–85 |  |
Smoking history | Â | Â | Â | 0.001* |
 Never-smoker | 48 (39.7) | 24 (50) | 24 (50) |  |
 Ever-smoker | 73 (60.3) | 58 (79.5) | 15 (20.5) |  |
Clinical TNM stage | Â | Â | Â | 0.170 |
 I–II | 53 (43.8) | 32 (60.4) | 21 (39.6) |  |
 III–IV | 68 (56.2) | 50 (73.5) | 18 (26.5) |  |
Histopathology | Â | Â | Â | 0.001* |
 ADC | 80 (66.1) | 45 (56.3) | 35 (43.7) |  |
 SCC | 33 (27.3) | 29 (87.9) | 4 (12.1) |  |
 NOS | 8 (6.6) | 8 (100) | 0 (0) |  |
CEA | Â | Â | Â | 0.323 |
 Positive | 45 (37.2) | 28 (62.2) | 17 (37.8) |  |
 Negative | 76 (62.8) | 54 (71.1) | 22 (28.9) |  |
CYFRA21-1 | Â | Â | Â | 0.006* |
 Positive | 61 (51.3) | 49 (80.3) | 12 (19.7) |  |
 Negative | 58 (48.7) | 32 (55.2) | 26 (44.8) |  |
SCC-Ag | Â | Â | Â | 0.058 |
 Positive | 36 (30.3) | 29 (80.6) | 7 (19.4) |  |
 Negative | 83 (69.7) | 52 (62.7) | 31 (37.3) |  |
NSE | Â | Â | Â | 0.999 |
 Positive | 3 (2.5) | 2 (66.7) | 1 (33.3) |  |
 Negative | 116 (97.5) | 79 (68.1) | 37 (31.9) |  |
CA125 | Â | Â | Â | 0.845 |
 Positive | 52 (43.0) | 36 (69.2) | 16 (30.8) |  |
 Negative | 69 (57.0) | 46 (66.7) | 23 (33.3) |  |
CA50 | Â | Â | Â | 0.144 |
 Positive | 15 (12.8) | 13 (86.7) | 2 (13.3) |  |
 Negative | 102 (87.2) | 68 (66.7) | 34 (33.3) |  |
CA72-4 | Â | Â | Â | 0.548 |
 Positive | 15 (12.8) | 12 (80.0) | 3 (20.0) |  |
 Negative | 102 (87.2) | 70 (68.6) | 32 (31.4) |  |
Ferritin | Â | Â | Â | 0.103 |
 Positive | 44 (36.4) | 26 (59.1) | 18 (40.9) |  |
 Negative | 77 (63.6) | 56 (72.7) | 21 (27.3) |  |